European Biosimilars Makers Weigh in on Latest Draft Guidelines

Manufacturers developing biosimilars in Europe want regulators to go back to comparing their therapies with the reference product based on the actual amount of active ingredient in a dose rather than a proposed standard that compares dosages and routes of administration.
Generic Line